Altimmune, Inc.

Informe acción NasdaqGM:ALT

Capitalización de mercado: US$617.4m

Salud financiera de hoja de balance de Altimmune

Salud financiera controles de criterios 6/6

Altimmune tiene un patrimonio de los accionistas total de $133.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $147.9M y $14.5M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$139.38m
PatrimonioUS$133.38m
Total pasivoUS$14.49m
Activos totalesUS$147.86m

Actualizaciones recientes sobre salud financiera

Recent updates

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Nov 13

Regulatory And Clinical Catalysts Ahead For Altimmune

Oct 28

Consider Buying Potential Takeover Target Altimmune

Oct 02

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Sep 21

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Sep 12
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Aug 27

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

May 27

Buy Altimmune's Potential Market Disruption With Pemvidutide

Apr 12

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11
Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12
Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27
We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

Reassessing Altimmune

Sep 07

Altimmune sets new 52-week high on rising volume

Aug 31

Altimmune Q2 2022 Earnings Preview

Aug 10

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Jun 29

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Jun 27
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune's New Avatar As A Liver Disease Player

Apr 07

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Feb 01
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune: Changing Focus To Pemvidutide In 2022

Jan 03

Altimmune: Changing The Thesis

Oct 16

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($145.8M) de ALT superan a sus pasivos a corto plazo ($8.6M).

Pasivo a largo plazo: Los activos a corto plazo de ALT ($145.8M) superan a sus pasivos a largo plazo ($5.8M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: ALT está libre de deudas.

Reducción de la deuda: ALT no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 0.2%.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ALT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: ALT dispone de suficiente cash runway para 1.6 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 28.3% cada año.


Descubre empresas con salud financiera